BioGaia
109.5
SEK
-0.36 %
BIOG B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
-0.36%
+6.1%
-4.95%
-12.54%
+8.2%
+10.16%
+6.73%
+32.73%
+1,441.54%
BioGaia is a biotechnology company. The company develops, markets and sells probiotic products. The products are mainly based on the bacterium Lactobacillus, which has probiotic effects. Today, the company's products are sold around the global market. Research and development are conducted via the company's external network of research institutions and clinics. The head office is located in Stockholm.
Read moreMarket cap
11.08B SEK
Turnover
13.13M SEK
Revenue
1.3B
EBIT %
34.18 %
P/E
30.25
Dividend yield-%
6.3 %
Financial calendar
12.2
2025
Annual report '24
7.5
2025
General meeting '24
7.5
2025
Interim report Q1'25
ShowingAll content types
BioGaia, Audiocast with teleconference, Q3'24
BioGaia AB: Interim Management Statement January - September 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools